1.Achim AM, Maziade M, Raymond E, etal. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011; 37(4): 811–821.
2.Tranulis C, Potvin S, Gourgue M, etal. The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectr. 2005; 10(5): 356–361.
3.Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012; 10(1): 88–95.
4.Cunill R, Castells X, Simeon D. Relationship between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009; 70(1): 70–82.
5.Mukhopadhaya K, Krishnaiah R, Taye T, etal. Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause of clinical concern. J Psychopharmacol. 2009; 23(1): 6–13.
6.Sterk B, Lankreijer K, Linszen DH, de Haan L. Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis: onset and relationship to psychotic symptoms. Aust N Z J Psychiatry. 2011; 45(5): 400–405.
7.Zink M, Knopf U, Kuwilsky A. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia. Aust N Z J Psychiatry. 2007; 41(3): 293–294.
8.Lim M, Park DY, Kwon JS, Joo YH, Hong KS. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol. 2007; 27(6): 712–713.
9.deHaan L, Sterk B, Wouters L, Linszen DH. The 5-years course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull. 2013; 39(1): 151–160.
10.Hwang MY, Kim SW, Yum SY, Opler LA. Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am. 2009; 32(4): 835–851.
11.Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(3): 333–346.
12.Alevizos B, Papageorgiou C, Christodoulou GN. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol. 2004; 7(3): 375–377.
13.Ke CL, Yen CF, Chen CC, etal. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci. 2004; 20(6): 295–301.
14.Ozer S, Arsava M, Ertugrul A, Demir B. Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(4): 724–727.
15.Stamouli S, Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol. 2006; 26(4): 396–400.
16.Baker RW, Chengappa KN, Baird JW, etal. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992; 53(12): 439–442.
17.deHaan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999; 60(6): 364–365.
18.Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci. 2005; 59(2): 219–222.
19.Mahendra R, Liew E, Subramaniam M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry. 2007; 68(4): 542–545.
20.Sa AR, Hounie AG, Sampaio AS, etal. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry. 2009; 50(5): 437–442.
21.deHaan L, Oekeneva A, Van Amelsvoort T, Linszen D. Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. Eur Psychiatry. 2004; 19(8): 524.
22.Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004; 18(14): 989–1010.
23.Schirmbeck F, Esslinger C, Rausch F, etal. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011; 41(11): 2361–2373.
24.Schirmbeck F, Rausch F, Englisch S, etal. Differential effects of antipsychotics agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. J Psychopharmacol. 2013; 27(4): 349–357.
25.Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012; 165(5): 1543–1555.
26.Pallanti S, Grassi G, Cantisani A. Approaches to treatment resistance. In: Zohar J, ed. Obsessive-Compulsive Disorder: Current Science and Clinical Practice. Hoboken, NJ: John Wiley & Sons; 2012; 99–134.
27.Kwon JS, Joo YH, Nam HJ, etal. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry. 2009; 66(11): 1233–1241.
28.Schirmbeck F, Nieratschker V, Frank J, etal. Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents. Psychiatr Genet. 2012; 22(5): 245–252.
29.Cai J, Zhang W, Yi Z, etal. Influence of polymorphism in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl). 230(1): 49–55.
30.Poyurovsky M, Fuchs C, Faragian S, etal. Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry. 2006; 51(12): 746–754.
31.Bienvenu OJ, Samuels JF, Wuliek LA, etal. Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective. Psychol Med. 2012; 42(1): 1–13.
32.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
33.First MB, Spritzer RL, Gibbon M, Willians JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient Edition (Version 2.0). Biometric Research Department. New York: New York State Psychiatric Institute; 1995.
34.Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
35.Montogomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382–389.
36.Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1): 50–55.
37.Goodman W, Price L, Rasmussen S, etal. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part I: development, use, and reliability. Arch Gen Psychiatry. 1989; 46: 1006–1011.
38.Goodman W, Price L, Rasmussen S, etal. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry. 1989; 46(11): 1012–1016.
39.Greeven A, Spinhoven P, van Balkom AJ. Hypochondriasis Y-BOCS: a study of the psychometric properties of a clinician-administered semi-structured interview to assess hypochondriacal thoughts and behaviours. Clin Psychol Psychother. 2009; 16(5): 431–443.
40.Hall RC. Global assessment of functioning: a modified scale. Psychosomatics. 1995; 36(3): 267–275.
41.Starcevic V. Hypochondriasis and health anxiety: conceptual challenges. Br J Psychiatry. 2013; 202(1): 7–8.
42.Hiller W, Fichter MM. High utilizers of medical care: a crucial subgroup among somatizing patients. J Psychosom Res. 2004; 56(4): 437–443.
43.deHaan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002; 63(2): 104–107.